Targets, Therapies and the Role of Serial Biopsies for Prognostication and Assessing Changes to Tumour Biology in Oesophageal and Oesophagogastric Junction Cancers

Oesophageal and oesophagogastric junction cancers represent a significant burden to public health. Clinical practice guidelines recommend treatment based on cellular molecular targets from tissue obtained before initiating therapy, including human epidermal growth factor receptor, microsatellite instability, mismatch repair, programmed death-ligand 1 neurotrophic receptor tyrosine kinase gene fusions. The expression of these markers the detection circulating tumour cells DNA in oesophageal are temporally variable following treatment. Together, findings may help individualize stratify patients at high risk disease progression recurrence.